Back to top
more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.53 USD

0.53
299,438

0.00 (-0.39%)

Updated Jul 3, 2024 01:00 PM ET

After-Market: $0.52 -0.01 (-1.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanghamitra Saha headshot

Bet on Rising Price-to-Earnings With 5 Top Stocks

by Sanghamitra Saha

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Aclaris (ACRS) Surges: Stock Moves 5.4% Higher

by Zacks Equity Research

Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Pacira (PCRX) Provides Preliminary Results for Second Quarter

by Zacks Equity Research

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.

Acceleron (XLRN) in Focus: Stock Moves 5.3% Higher

by Zacks Equity Research

Acceleron (XLRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

    Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher

    by Zacks Equity Research

    Zogenix (ZGNX) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

    Corcept Begins Enrollment in Phase III Pancreatic Cancer Study

    by Zacks Equity Research

    Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

    CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study

    by Zacks Equity Research

    CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.

    GlycoMimetics (GLYC) in Focus: Stock Moves 8.1% Higher

    by Zacks Equity Research

    GlycoMimetics (GLYC) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

    Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate

    by Zacks Equity Research

    Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.

    Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval

    by Zacks Equity Research

    FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.

    Top Ranked Momentum Stocks to Buy for May 29th

    by Zacks Equity Research

    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 29th.

    BioLineRx Concludes Recruitment in Pancreatic Cancer Study

    by Zacks Equity Research

    BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

    BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

    by Zacks Equity Research

    The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

    BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors

    by Zacks Equity Research

    BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.

    Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    Tenet Healthcare's (THC) second-quarter earnings are likely to suffer due to lower revenues.

    BioCryst Down Despite Hereditary Angioedema Study Meets Goal

    by Zacks Equity Research

    BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.

    BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade

    by Zacks Equity Research

    BioLineRx (BLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Can The Uptrend Continue for BioLineRx (BLRX)?

    by Zacks Equity Research

    Investors certainly have to be happy with BioLineRx Ltd. (BLRX) and its short term performance.

    BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher

    by Zacks Equity Research

    BioLineRx (BLRX) shares rose nearly 8% in the last trading session, amid huge volumes.

      BioLineRx Stock Up on Stake Increase in Lead Cancer Program

      by Zacks Equity Research

      BioLineRx (BLRX) signs an agreement with Biokine Therapeutics to raise its economic interest in its lead oncology platform, BL-8040, by 20%.

        Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status

        by Zacks Equity Research

        Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.

          BioLineRx (BLRX) Continue to Surge Higher?

          by Zacks Equity Research

          As of late, it has definitely been a great time to be an investor in BioLineRx Ltd. (BLRX).

            CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

            by Zacks Equity Research

            CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

              VIVUS' PAH Candidate Data Positive in Early Stage Study

              by Zacks Equity Research

              VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

                Aclaris' Alopecia Candidate Gets Fast Track Designation

                by Zacks Equity Research

                The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.